KRAS mutations constitute a poor prognostic marker in NSCLC and colorectal cancer, however, its prognostic characteristic in cervical cancer remains to be elucidated.44,45 To date, RAS proteins have not yielded successful targeted therapies. This evidence concerns the gene KRAS and non-small cell lung carcinoma.